| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Ticagrelor (JAN/USAN/INN); Brilinta (TN) | ||||||||||
| Product | BRILINTA (AstraZeneca Pharmaceuticals LP), BRILINTA (Cardinal Health 107) | ||||||||||
| Generic | TICAGRELOR (Amneal Pharmaceuticals NY LLC) | ||||||||||
| Formula | C23H28F2N6O4S | ||||||||||
| Exact mass | 522.1861 | ||||||||||
| Mol weight | 522.568 | ||||||||||
| Structure |  | ||||||||||
| Class | Blood modifier agent DG01950 Antithrombotic agent DG01712 Antiplatelet agent DG01809 P2Y12 receptor antagonist Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate Metabolizing enzyme inhibitor DG02852 CYP3A/CYP3A4 inhibitor Transporter substrate DG01665 ABCB1 substrate Transporter inhibitor DG01622 ABCB1 inhibitor | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Platelet aggregation inhibitor, Purinergic receptor P2Y12 antagonist | ||||||||||
| Disease | Myocardial infarction [DS:H01730] | ||||||||||
| Comment | Prevention of thromboembolic events in patients with acute coronary syndrome | ||||||||||
| Target | P2RY12 [HSA:64805] [KO:K04298] | ||||||||||
| Pathway |
| ||||||||||
| Metabolism | Enzyme: CYP3A [HSA:1576 1577 1551] Transporter: ABCB1 [HSA:5243] | ||||||||||
| Interaction | CYP inhibition: CYP3A [HSA:1576 1577 1551] Transporter inhibition: ABCB1 [HSA:5243] | ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] B BLOOD AND BLOOD FORMING ORGANS B01 ANTITHROMBOTIC AGENTS B01A ANTITHROMBOTIC AGENTS B01AC Platelet aggregation inhibitors excl. heparin B01AC24 Ticagrelor D09017 Ticagrelor (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Blood Products and Modifiers Platelet Modifying Agents Adenosine Diphosphate P2Y12 Ticagrelor D09017 Ticagrelor (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 33 Blood and body fluid agents 339 Miscellaneous 3399 Others D09017 Ticagrelor (JAN/USAN/INN) Drug groups [BR:br08330] Blood modifier agent DG01950 Antithrombotic agent DG01712 Antiplatelet agent D09017 Ticagrelor DG01809 P2Y12 receptor antagonist D09017 Ticagrelor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate D09017 Ticagrelor Metabolizing enzyme inhibitor DG02852 CYP3A/CYP3A4 inhibitor D09017 Ticagrelor Transporter substrate DG01665 ABCB1 substrate D09017 Ticagrelor Transporter inhibitor DG01622 ABCB1 inhibitor D09017 Ticagrelor Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Purine / pyrimidine P2RY12 D09017 Ticagrelor (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D09017 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D09017 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D09017 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D09017 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D09017 Drug transporters D09017 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D09017 | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 36 1 C8y C 16.5612 -16.1984 2 N5x N 16.5612 -17.6066 3 C8y C 17.7582 -18.3108 4 C8y C 19.0256 -17.6066 5 C8y C 19.0256 -16.1984 6 N5x N 17.7582 -15.4943 7 N5x N 20.3634 -18.0291 8 N5x N 21.1379 -16.9025 9 N4y N 20.3634 -15.7759 10 S2a S 15.3642 -15.4943 11 C1b C 14.1672 -16.1984 12 C1b C 12.9702 -15.4943 13 C1a C 11.7732 -16.1984 14 N1b N 17.7582 -19.7190 15 C1y C 16.5612 -20.4231 16 C1y C 15.1529 -20.4231 17 C1x C 15.8570 -21.6201 18 C8y C 13.9559 -19.7190 19 C8x C 13.9559 -18.3108 20 C8x C 12.7589 -17.6066 21 C8y C 11.5619 -18.3108 22 C8y C 11.5619 -19.7190 23 C8x C 12.7589 -20.4231 24 X F 10.3649 -17.6066 25 X F 10.3649 -20.4231 26 C1y C 20.8563 -14.4381 27 C1x C 22.1941 -14.0156 28 C1y C 22.1941 -12.6074 29 C1y C 20.8563 -12.1145 30 C1y C 20.0113 -13.2411 31 O1a O 18.6031 -13.2411 32 O1a O 20.4338 -10.7767 33 C1b C 25.7851 -11.9033 34 O1a O 26.9821 -12.6074 35 C1b C 24.5881 -12.6074 36 O2a O 23.3911 -11.9033 BOND 40 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 4 7 1 8 7 8 2 9 8 9 1 10 5 9 1 11 1 10 1 12 10 11 1 13 11 12 1 14 12 13 1 15 3 14 1 16 15 14 1 #Down 17 16 15 1 18 17 16 1 19 15 17 1 20 16 18 1 #Up 21 18 19 2 22 19 20 1 23 20 21 2 24 21 22 1 25 22 23 2 26 18 23 1 27 21 24 1 28 22 25 1 29 26 9 1 #Up 30 26 27 1 31 27 28 1 32 28 29 1 33 29 30 1 34 26 30 1 35 30 31 1 #Down 36 29 32 1 #Down 37 33 34 1 38 33 35 1 39 35 36 1 40 28 36 1 #Up |